Biomark Diagnostics Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

DB:20B Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
29 Nov 24Buy€149Guoyu HuangIndividual1,000€0.15
28 Nov 24Buy€311Rashid Ahmed BuxIndividual2,000€0.16
22 Nov 24Buy€794Rashid Ahmed BuxIndividual5,500€0.14
21 Nov 24Buy€615Guoyu HuangIndividual4,500€0.14
15 Nov 24Buy€161Rashid Ahmed BuxIndividual1,020€0.16
15 Nov 24Buy€316Guoyu HuangIndividual2,000€0.16
11 Nov 24Buy€936Guoyu HuangIndividual6,000€0.16
08 Nov 24Buy€1,295Rashid Ahmed BuxIndividual8,400€0.15
25 Oct 24Buy€626Guoyu HuangIndividual4,000€0.16
10 Oct 24Buy€489Guoyu HuangIndividual3,000€0.16
10 Sep 24Buy€83Rashid Ahmed BuxIndividual500€0.17
10 Sep 24Buy€167Guoyu HuangIndividual1,000€0.17
22 Aug 24Buy€2,117Rashid Ahmed BuxIndividual15,200€0.14
22 Aug 24Buy€427Guoyu HuangIndividual3,000€0.14
20 Aug 24Buy€29,061Guoyu HuangIndividual200,000€0.15
20 Aug 24Sell€29,061Bux Investments Ltd.Company200,000€0.15
09 Aug 24Buy€760Guoyu HuangIndividual5,300€0.14
09 Aug 24Buy€1,149Rashid Ahmed BuxIndividual7,800€0.15
08 Aug 24Buy€180Guoyu HuangIndividual1,200€0.15
01 Aug 24Buy€193Rashid Ahmed BuxIndividual1,200€0.16
01 Aug 24Buy€328Guoyu HuangIndividual2,000€0.16
25 Jul 24Buy€733Guoyu HuangIndividual5,000€0.15
12 Jul 24Buy€1,014Rashid Ahmed BuxIndividual7,000€0.14
11 Jul 24Buy€871Guoyu HuangIndividual6,000€0.15
05 Jul 24Buy€277Rashid Ahmed BuxIndividual1,700€0.16
04 Jul 24Buy€245Guoyu HuangIndividual1,500€0.16
21 Jun 24Buy€115Rashid Ahmed BuxIndividual700€0.16
20 Jun 24Buy€245Guoyu HuangIndividual1,500€0.16
14 Jun 24Buy€326Guoyu HuangIndividual2,000€0.16
08 Jun 24Buy€619Guoyu HuangIndividual4,000€0.15
07 Jun 24Buy€377Rashid Ahmed BuxIndividual2,600€0.15
30 May 24Buy€1,515Guoyu HuangIndividual10,200€0.15
29 May 24Buy€148Rashid Ahmed BuxIndividual1,000€0.15
24 May 24Buy€152Guoyu HuangIndividual1,000€0.15
23 May 24Buy€645Rashid Ahmed BuxIndividual4,250€0.15
16 May 24Buy€1,979Rashid Ahmed BuxIndividual10,800€0.19
16 May 24Buy€744Guoyu HuangIndividual4,000€0.19
01 May 24Buy€293Rashid Ahmed BuxIndividual1,500€0.20
01 May 24Buy€391Guoyu HuangIndividual2,000€0.20
25 Apr 24Buy€164Rashid Ahmed BuxIndividual800€0.20
19 Apr 24Buy€152Rashid Ahmed BuxIndividual750€0.20
18 Apr 24Buy€1,916Guoyu HuangIndividual10,500€0.19
18 Apr 24Buy€2,578Rashid Ahmed BuxIndividual13,800€0.20
11 Apr 24Buy€758Rashid Ahmed BuxIndividual3,700€0.21
11 Apr 24Buy€953Guoyu HuangIndividual5,000€0.19
15 Mar 24Buy€224Rashid Ahmed BuxIndividual1,100€0.20
08 Mar 24Buy€305Guoyu HuangIndividual1,500€0.20
20 Feb 24Buy€106Rashid Ahmed BuxIndividual500€0.21
08 Feb 24Buy€323Rashid Ahmed BuxIndividual1,600€0.22
02 Feb 24Buy€197Rashid Ahmed BuxIndividual1,000€0.20

Insider Trading Volume

Insider Buying: 20B insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of 20B?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders6,144,7826.76%
General Public39,077,78143%
Private Companies45,663,66650.2%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 5 shareholders own 57% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
45.1%
Biomark Technologies Inc
41,004,167€5.1m0%no data
5.32%
Guoyu Huang
4,830,712€603.8k4.78%no data
4.67%
Bux Investments Ltd.
4,247,411€530.9k0%no data
1.45%
Rashid Ahmed Bux
1,314,070€164.3k1.3%no data
0.45%
Grg Consulting Ltd.
412,088€51.5k-32.7%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 02:33
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biomark Diagnostics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution